Aflac Incorporated (AFL - Free Report) is scheduled to release third-quarter 2021 results on Oct 27, after the market closes.
Q3 Estimates
The Zacks Consensus Estimate for the company’s earnings per share is pegged at $1.30, indicating a fall of 6.47% from the prior-year quarter’s reported figure. The consensus mark for revenues stands at $5.38 billion, which suggests a decline of 4.97% from the year-ago quarter’s reported number.
Factors to Impact Q3 Results
At Aflac’s Japan segment, revenues are likely to have gained from increased premium, driven by higher sales of its new medical product and improved pandemic conditions compared with the prior-year scenario.
At the U.S. segment, sales are likely to have gone up, aided by improved pandemic conditions.
Net investment income is likely to have gone up, primarily on higher variable net investment income.
Expenses are likely to have been high, weighing down the margins. Constant digital investments in its core technological platforms and their upgrades might have flared up costs. However, the company is trying to control costs wherever possible and to this end, it took numerous cost-curbing measures, which might have partially offset the stress on margins.
Earnings Surprise History
The company boasts an impressive earnings surprise history as its bottom line beat estimates in each of the trailing four quarters, the average being 19.92%. This is depicted in the chart below:
What Our Quantitative Model Predicts
The proven Zacks model predicts an earnings beat for Aflac this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.
Earnings ESP: Aflac has an Earnings ESP of +1.44%. This is because the Most Accurate Estimate of $1.32 is pegged higher than the Zacks Consensus Estimate of $1.30. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Aflac has a Zacks Rank #2, currently.
Other Stocks to Consider
Here are some other stocks worth considering from the insurance space with the perfect mix of elements to surpass estimates in their upcoming releases.
Cigna Corp. (CI - Free Report) currently has an Earnings ESP of +2.19% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here..
Athene Holding Ltd. currently has an Earnings ESP of +1.71% and is a Zacks #2 Ranked stock.
MetLife, Inc. (MET - Free Report) currently has an Earnings ESP of +1.21% and is a Zacks #3 Ranked stock.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Aflac Incorporated (AFL - Free Report) is scheduled to release third-quarter 2021 results on Oct 27, after the market closes.
Q3 Estimates
The Zacks Consensus Estimate for the company’s earnings per share is pegged at $1.30, indicating a fall of 6.47% from the prior-year quarter’s reported figure. The consensus mark for revenues stands at $5.38 billion, which suggests a decline of 4.97% from the year-ago quarter’s reported number.
Factors to Impact Q3 Results
At Aflac’s Japan segment, revenues are likely to have gained from increased premium, driven by higher sales of its new medical product and improved pandemic conditions compared with the prior-year scenario.
At the U.S. segment, sales are likely to have gone up, aided by improved pandemic conditions.
Net investment income is likely to have gone up, primarily on higher variable net investment income.
Expenses are likely to have been high, weighing down the margins. Constant digital investments in its core technological platforms and their upgrades might have flared up costs. However, the company is trying to control costs wherever possible and to this end, it took numerous cost-curbing measures, which might have partially offset the stress on margins.
Earnings Surprise History
The company boasts an impressive earnings surprise history as its bottom line beat estimates in each of the trailing four quarters, the average being 19.92%. This is depicted in the chart below:
What Our Quantitative Model Predicts
The proven Zacks model predicts an earnings beat for Aflac this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.
Earnings ESP: Aflac has an Earnings ESP of +1.44%. This is because the Most Accurate Estimate of $1.32 is pegged higher than the Zacks Consensus Estimate of $1.30. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Aflac has a Zacks Rank #2, currently.
Other Stocks to Consider
Here are some other stocks worth considering from the insurance space with the perfect mix of elements to surpass estimates in their upcoming releases.
Cigna Corp. (CI - Free Report) currently has an Earnings ESP of +2.19% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here..
Athene Holding Ltd. currently has an Earnings ESP of +1.71% and is a Zacks #2 Ranked stock.
MetLife, Inc. (MET - Free Report) currently has an Earnings ESP of +1.21% and is a Zacks #3 Ranked stock.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MET - FREE
Get the latest research report on AFL - FREE
Get the latest research report on CI - FREE